Metallopeptidase Inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer by Nordgaard, Cathrine et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Metallopeptidase Inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling
in colorectal cancer
Nordgaard, Cathrine; Doll, Sophia; Matos, Ana Laura de Souza Almeida; Høeberg, Mikkel;
Kazi, Julhash Uddin; Friis, Stine; Stenvang, Jan; Rönnstrand, Lars; Mann, Matthias; Moreira,
José Manuel Afonso
Published in:
Molecular Oncology
DOI:
10.1002/1878-0261.12575
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Nordgaard, C., Doll, S., Matos, A. L. D. S. A., Høeberg, M., Kazi, J. U., Friis, S., ... Moreira, J. M. A. (2019).
Metallopeptidase Inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer.
Molecular Oncology, 13(12), 2646-2662. https://doi.org/10.1002/1878-0261.12575
Download date: 03. Feb. 2020
Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor
tyrosine kinase c-Kit signaling in colorectal cancer
Cathrine Nordgaard1, Sophia Doll2,3, Ana Laura de Souza Almeida Matos1, Mikkel Høeberg1,
Julhash Uddin Kazi4, Stine Friis1, Jan Stenvang1, Lars R€onnstrand4,5 , Matthias Mann2,3 and
Jose Manuel Afonso Moreira1
1 Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
2 Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
3 Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark
4 Division of Translational Cancer Research and Lund Stem Cell Center, Lund University, Sweden
5 Division of Oncology, Skane University Hospital, Lund, Sweden
Keywords
colorectal cancer; c-Kit; cetuximab;
predictive biomarkers; omics; invasion
Correspondence
J. M. A. Moreira, Department of Drug
Design and Pharmacology, Faculty of Health
and Medical Sciences, University of
Copenhagen, Jagtvej 162, Copenhagen,
Denmark
Tel: +45 35333116
E-mail: jomo@sund.ku.dk
(Received 12 March 2019, revised 13
August 2019, accepted 20 September 2019)
doi:10.1002/1878-0261.12575
Colorectal cancer (CRC) is the third most prevalent cancer worldwide
causing an estimated 700 000 deaths annually. Different types of treatment
are available for patients with advanced metastatic colorectal cancer,
including targeted biological agents, such as cetuximab, a monoclonal anti-
body that targets EGFR. We have previously reported a study indicating
multiple levels of interaction between metallopeptidase inhibitor 1 (TIMP-
1) and the epidermal growth factor (EGF) signaling axis, which could
explain how TIMP-1 levels can affect the antitumor effects of EGFR inhi-
bitors. We also reported an association between TIMP-1-mediated cell
invasive behavior and KRAS status. To gain insight into the molecular
mechanisms underlying the effects of TIMP-1 in CRC, we examined by
transcriptomics, proteomics, and kinase activity profiling a matched pair of
isogenic human CRC isogenic DLD-1 CRC cell clones, bearing either an
hemizygous KRAS wild-type allele or KRAS G13D mutant allele, exposed,
or not, to TIMP-1. Omics analysis of the two cell lines identified the recep-
tor tyrosine kinase c-Kit, a proto-oncogene that can modulate cell prolifer-
ation and invasion in CRC, as a target for TIMP-1. We found that
exposure of DLD-1 CRC cells to exogenously added TIMP-1 promoted
phosphorylation of c-Kit, indicative of a stimulatory effect of TIMP-1 on
the c-Kit signaling axis. In addition, TIMP-1 inhibited c-Kit shedding in
CRC cells grown in the presence of exogenous TIMP-1. Given the regula-
tory roles that c-Kit plays in cell proliferation and migration, and the real-
ization that c-Kit is an important oncogene in CRC, it is likely that some
of the biological effects of TIMP-1 overexpression in CRC may be exerted
through its effect on c-Kit signaling.
Abbreviations
CE, cellular extracts; CM, conditioned media; CRC, colorectal cancer; DAPI, 40,6-diamidino-2-phenylindole; ECM, extracellular matrix; EGF,
epidermal growth factor; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; MS, mass spectrometry; PLA, proximity
ligation assay; RTK, receptor tyrosine kinase; STK, serine/threonine kinase; TIMP-1, metallopeptidase inhibitor 1; TK, tyrosine kinase;
TRIM59, tripartite motif-containing 59; Y2H, yeast two-hybrid.
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1. Introduction
Metallopeptidase Inhibitor 1 (TIMP-1) was originally
discovered as a serum protein responsible for collage-
nase inhibition and growth of erythroid progenitor cells
and is one of the four known endogenous human metal-
lopeptidase inhibitors (TIMP-1 through TIMP-4).
TIMP-1 is expressed in various tissues, including colon,
and as the name suggests, it inhibits matrix metallopro-
teinases (MMPs), a family of peptidases regulating
extracellular matrix (ECM) turnover. TIMPs and
MMPs regulate tumor invasion, migration, and pro-
gression through tissue remodeling. Accordingly, one
would expect TIMP-1 to exert mainly a beneficial effect
on cancer outcomes, by inhibiting remodeling of the
ECM and therefore blocking invasion and metastasis.
However, regulatory effects on cell proliferation and
survival have also been reported for TIMP-1, with both
positive and negative effects on tumor growth and pro-
gression reported (Hornebeck et al., 2005). Available
evidence suggests TIMP-1 to work in a dual way, regu-
lating cellular functions by both MMP-dependent and
MMP-independent mechanisms. Structurally, TIMP-1
consists of two distinct and independent structural
domains: an N-terminal domain, spanning the MMP-
inhibitory activity, and a C-terminal domain thought to
hold some of the MMP-independent cytokine-like activ-
ities of TIMP-1 (Chesler et al., 1995; Gasson et al.,
1985; Herszenyi et al., 2012; Stetler-Stevenson, 2008).
The localization of TIMP-1 may be crucial to explain its
dual effects: Extracellular TIMP-1 confined to the ECM
prevents metastasis by inhibiting nearby MMPs,
whereas intracellular TIMP-1 promotes cancer cell pro-
liferation and survival by effecting different signaling
pathways. These different effects may also be modu-
lated by different interaction partners. TIMP-1 interacts
with a complex of the tetraspanin cluster of differentia-
tion 63 (CD63) and integrin b1 at the cell membrane
(Jung et al., 2006), and CD63 down-regulation
decreases TIMP-1 presence at the cell surface and
reduces cell survival in breast cancer cells. The TIMP-1–
CD63–integrin b1 complex can also stimulate Src phos-
phorylation, followed by activation of yes-associated
protein and transcriptional co-activator with PDZ bind-
ing domain, which in turn promote cancer cell prolifera-
tion (Ando et al., 2018). TIMP-1 also interacts with a
complex of the cell surface glycoprotein cluster of differ-
entiation 44 and pro-MMP-9, and these mediate TIMP-
10s antiapoptotic effects in erythroid cells (Lambert
et al., 2009). In addition, TIMP-1 can also up-regulate
RAS and MAPK activity, possibly through activation
of receptor tyrosine kinases (RTKs) (Akahane et al.,
2004; Wang et al., 2002; Yamashita et al., 1996).
Recently, we found that TIMP-1 plasma levels pre-
dicted benefit from EGFR-inhibition therapy in
KRAS-mutated metastatic colorectal cancer patients.
These results were supported by data from cellular
models showing that exposure of colorectal cancer
(CRC) cells to exogenously added recombinant TIMP-
1 promoted a more aggressive behavior in these cells,
specifically in KRAS-mutated cells (Tarpgaard et al.,
2016). We added recombinant TIMP-1 to a matched
set of isogenic DLD-1 CRC cell clones, in which either
the endogenous KRAS wt allele (from here on referred
to as DLD-1 G13D cell line) or the KRAS(G13D)
mutant allele (from here on referred to as DLD-1 wt
cell line) has been inactivated by targeted homologous
recombination (Yun et al., 2009), respectively.
Whereas the DLD-1 wt cells showed no significant dif-
ference in invasive potential, DLD-1 G13D cells
responded to the presence of TIMP-1 in the growth
medium by becoming significantly more invasive
(Tarpgaard et al., 2016).
To address the effect of TIMP-1 on the invasive
potential of CRC cells, we took a three-pronged
approach: We performed a comparative proteomic
analysis of the DLD-1 G13D and DLD-1 wt CRC
cells to identify differentially expressed proteins. We
also analyzed the transcriptome of DLD-1 G13D and
DLD-1 wt cells at baseline and following exposure to
TIMP-1 to identify changes caused by exposure to
TIMP-1. Finally, we performed a broad kinase activity
assay study of the DLD-1 G13D and DLD-1 wt cells
exposed to TIMP-1, to identify differential effects on
RTKs in these cells. As a result, we identified the
RTK c-Kit as a target of TIMP-1 in these cells. KIT
encodes the human homolog of the proto-oncogene c-
Kit, the cellular homolog of the transforming onco-
gene of the Hardy–Zuckerman 4 feline sarcoma virus
(Yarden et al., 1987). c-Kit is a RTK, and aberrant
expression or mutational activation of c-Kit is associ-
ated with a variety of diseases in humans, including
cancer (Heinrich et al., 2002; Lennartsson et al., 2005).
We found that TIMP-1 increased phosphorylation of
c-Kit, as well as corresponding targets, and inhibited
c-Kit shedding. In summary, our data provide some
further mechanistic insight into the effects of TIMP-1
on CRC cells.
2. Materials and Methods
2.1. Cell culture
A set of isogenic colorectal adenocarcinoma cell lines,
derived from the DLD-1 CRC line by targeted
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homologous recombination of the KRAS locus, were
used in this study (Yun et al., 2009): The KRAS-mu-
tated (KRASG13D/) DLD-1 cell line (referred to as
DLD-1 G13D) was generated by knockout of the
wild-type KRAS allele in heterozygous DLD-1 paren-
tal cells (KRASG13D/+), whereas the KRAS wild-type
(KRAS+/) DLD-1 cell line (referred to as DLD-1 wt)
was generated by knockout of the mutant KRAS
allele, respectively. The cell lines were kindly provided
by Bert Vogelstein (Johns Hopkins University, USA).
All cell lines were grown under sterile conditions at
37 °C and 5% CO2 in McCoy’s 5A medium (Invitro-
gen, Carlsbad, CA, USA). Growth media were supple-
mented with 10% FBS (Invitrogen), unless stated
otherwise. To investigate the role of TIMP-1, cells
were stimulated with 1 or 5 µgmL1 N-glycosylated
recombinant His6-tagged human TIMP-1, as described
(Vinther et al., 2014). As control, cells were stimulated
with vehicle (PBS) or with an equivalent amount of
BSA, as appropriate (Roche Diagnostics, Basel,
Switzerland). The murine pro-B cell line Ba/F3 was
maintained in RPMI 1640 medium supplemented with
10% heat-inactivated FBS and 10 ngmL1 recombi-
nant murine IL-3 (Prospec Tany, Rehovot, Israel)
(Pedersen et al., 2009). The identity of all cell lines
used was verified by short tandem repeat loci profiling
(IdentiCell, Aarhus, Denmark).
2.2. Western blot analysis
For protein extractions, we used the Mammalian Pro-
tein Extraction Reagent (M-PER; Thermo Fisher Sci-
entific, Waltham, MA, USA) supplemented with Pierce
Protease and Phosphatase Inhibitor Mini Tablets
(Thermo Fisher Scientific). The lysates were cen-
trifuged at 14 000 g for 10 min to remove cell debris,
and protein concentrations were determined using
Thermo Scientific Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific). The samples were diluted
with Laemmli sample buffer (Sigma-Aldrich, St. Louis,
MI, USA) to contain ~ 20 µg protein in 25 µL total
volume or 15 µg protein in 15 µL total volume,
depending on the use of either 10- or 15-well gels (4–
15% Mini-PROTEAN TGCTM gel; Bio-Rad, Her-
cules, CA, USA). Samples were incubated at 70 °C for
10 min prior to loading. The protein samples were
resolved on a gel using Bio-Rad SDS System (Bio-
Rad) and blotted onto a 0.2-µm nitrocellulose mem-
brane (Trans-Blot TurboTM Midi Nitrocellulose
Transfer Pack; Bio-Rad). Membranes were blocked
with 5% skim milk powder (Merck Life Sciences,
Darmstadt, Germany) or 5% BSA fraction V (Roche
Diagnostics) in TBS-T, before being incubated with
primary antibodies followed by a horseradish peroxi-
dase -conjugated secondary antibody in blocking buf-
fer. Protein bands were developed using either Clarity
Western ECL Substrate (Bio-Rad) or Amersham ECL
Select Western Blotting Detection Reagent (GE
Healthcare Life Sciences, Piscataway, NJ, USA), as
appropriate. Images were acquired with UVP BioSpec-
trum Imaging System (UVP, Upland, CA, USA), and
bands were quantified using the software (IMAGEJ ver-
sion 1.49, U. S. National Institutes of Health,
Bethesda, MD, USA).
2.3. Immunostaining
Cells were washed, trypsinized, and then fixed with
4% buffered formalin (Sigma-Aldrich). Following
extensive washings with PBS, cells were centrifuged to
form a pellet, which was kept in 70% EtOH (Sigma-
Aldrich) until embedded in paraffin. Before use,
embedded cells were freshly cut into 3-µm sections,
deparaffinized in xylene, and rehydrated through an
alcohol gradient. Sections were exposed to heat-in-
duced antigen retrieval and placed in EnVisionTM
FLEX Target Retrieval Solution, low pH (Dako,
Glostrup, Denmark) diluted 1 : 50 in MilliQ H2O and
boiled. For some of the experiments, cells were grown
on coverslips or in Permanox chamber slides (Lab-Tek
Chamber Slide System; Thermo Fisher Scientific) in
order to avoid trypsin treatment or cell scraping. The
surfaces were coated with poly-L-lysine (Sigma-
Aldrich) prior to seeding. Cells were washed twice with
ice-cold PBS prior to 20 min of fixation with 4% buf-
fered formalin. Cells were permeabilized with 0.05%
Triton X-100 in Tris-buffered saline (TBS; 20 mM Tris
pH 7.6, 150 mM NaCl) for 5 min at RT and washed
with 19 TBS. Coverslips and chamber slides were kept
in humidity chambers during all incubations. Prior to
incubation of primary antibody, sections were blocked
with 25% BSA in TBS before incubation with primary
antibodies. Sections were then incubated with sec-
ondary Alexa Fluor antibodies (Invitrogen) diluted in
25% BSA in TBS. Slides were mounted with ProLong
Gold Antifade Reagent with 4’,6-diamidino-2-
phenylindole (DAPI; Invitrogen) and examined by
confocal microscopy. All antibodies used in this study,
and the dilutions used, are listed in Table S1.
2.4. Proximity ligation assay
Proximity ligation assay (PLA) (Duolink; Olink Bio-
science, Uppsala, Sweden) was performed according to
the manufacturer’s instructions. Briefly, cell pellets
mounted on glass slides were blocked with Duolink
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blocking buffer for 30 min at 37 °C in humidity cham-
ber. Blocking buffer was tapped off, and primary anti-
bodies were diluted in Duolink Antibody Diluent
(TIMP-1: 1 : 4000 and c-Kit: 1 : 250). Slides were
mounted with cover plates, placed in cassettes or in
humidity chamber (for embedded cells vs chamber
slides), then incubated with either one of the antibod-
ies as control or both, and left to incubate at 4 °C
overnight. The following day slides were washed with
wash buffer A (Duolink) 2 9 5 min before released
from cassettes and incubated for 1 h at 37 °C with
both PLA probes diluted 1 : 5 in Antibody Diluent.
PLA probes were tapped off, and slides were washed
twice for 5 min with wash buffer A. Ligation stock
was diluted 1 : 5 in MilliQ water, and ligase was
diluted in the mixture 1 : 40. Ligation–ligase was
added to slides, which were then incubated 30 min at
37 °C and then tapped off. Sections were washed
2 9 2 min with wash buffer A. Amplification stock
was diluted 1 : 5, and polymerase was diluted 1 : 80 in
this mixture. Amplification–polymerase mixture was
added to the slides followed by incubation for 100 min
at 37 °C. Amplification-polymerase was tapped off,
and slides were washed once either for 10 min in wash
buffer B or for 5 min in wash buffer B, followed by
15-min incubation with Atto488 Phalloidin (Sigma-
Aldrich) diluted 1 : 100 in wash buffer B, and subse-
quently washed with wash buffer B for 10 min. Slides
were washed 1 min in 0.019 wash buffer B and dried
in the dark prior to mounting with Duolink In Situ
Mounting Medium with DAPI. Edges were sealed with
nail polish, and slides were imaged with confocal
microscopy.
2.5. Kinase activity assay
DLD-1 wt and DLD-1 G13D cells were serum-starved
for 4 h prior to 15-, 30-, and 120-min stimulations
with 5 µgmL1 TIMP-1 or vehicle. Cells were washed
with 39 cold PBS and lysed with M-PER lysis buffer.
Protein concentrations were measured, and samples
were diluted to equal concentration. Kinase activity
assay was performed using PamChip tyrosine kinase
(TK) and serine/threonine kinase (STK) arrays (Pam-
Gene, Hertogenbosch, the Netherlands). STK arrays
consist of 140 ser/thr-containing peptides. TK arrays
consist of 144 peptides with known phosphorylation
sites, representing 100 different proteins. Each peptide
represents a 15-amino-acid sequence of which 13 resi-
dues are derived from a putative phosphorylation site
present in human proteins. Peptide sequences are
derived from literature and are a cognate target of one
or multiple kinases. Activation status of represented
kinases is derived from the phosphorylation levels of
its combined cognate targets. Incubation, washing, dis-
pensing of reagents, and imaging of the PamChip were
performed automatically using the PamStation 12.
PamGene’s Bionavigator software was used for image
quantification, quality control, statistical analysis, visu-
alization, and interpretation. Downstream data analy-
sis was done using MetaCore pathway analysis
software (Thomson Reuters, Toronto, Canada).
2.6. c-Kit shedding ELISA kit
To measure TIMP-1’s effect on shedding of c-Kit to
the media, c-Kit (Soluble) (Human) ELISA Kit (Nor-
dic Biosite, Copenhagen, Denmark) was employed.
This kit measures the levels of soluble c-Kit as readout
for shedding of c-Kit. The experiments were performed
in accordance with the manufacturer’s instructions.
2.7. Gene expression assays
DLD-1 wt and DLD-1 G13D cells were cultured in
the presence, or absence, of TIMP-1 (5 µgmL1) for
4 h, washed thrice, and collected by trypsinization in
three independent, consecutive (passages 28, 29, and
30) experiments. The RNeasy Mini Kit (Qiagen,
Venlo, The Netherlands) was used to isolate RNA
from cells as described in the manufacturer’s protocol.
In order to optimize samples for gene expression
assay, samples were treated with RQ1 RNase-free
DNase (Promega, Madison, Wisconsin, WI, USA);
1 µL DNase was used per µg RNA, samples were
mixed with 1 µL reaction buffer, and RNase-free
water was added to a volume of 10 µL. Samples were
incubated at 37 °C for 30 min before 1 µL of DNase
stop solution was added followed by 10 min of incuba-
tion at 65 °C to terminate the reaction. Samples were
stored at 80 °C before processing.
Samples were analyzed at the Multi-Assay Core
Facility at the Danish Technical University (Center for
Biological Sequence Analysis, DTU) using Agilent
arrays. Briefly, samples were labeled using Low Input
Quick Amp Labeling Kits (One-Color; Agilent Tech-
nologies, Santa Clara, CA, USA) in accordance with
the manufacturer’s instructions. Arrays were processed
and data were collected using Agilent Feature Extrac-
tion Software (Agilent Technologies). Data analysis
was done using the PARTEK GENOMICS SUITE v7.0 soft-
ware package (Partek, St. Louis, MO, USA). Results
are presented as Log2FoldChange of DLD-1 wt vs
DLD-1 G13D, and TIMP-1-treated vs TIMP-1-un-
treated cells, genes were considered significantly differ-
ent expressed if P-value < 0.0075 and
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Log2FoldChange>+/-1. Multiple testing correction of
P-values was performed using the Benjamini–Hoch-
berg method (Benjamini and Hochberg, 1995).
2.8. In vitro wound healing assay
DLD-1 wt cells were plated at a density of 5 9 104
cells/well in 2-well silicone inserts (ibidi GmbH,
Gr€afelfing, Germany) and incubated at 37 °C for 24 h.
Then, inserts were removed leaving a 500-µm gap
without any cells. Dishes were cultured for 24 h in
McCoy’s 5A medium (Invitrogen), supplemented with
10% FBS (Invitrogen), and in the presence, or
absence, of TIMP-1 (5 µgmL1), imatinib mesylate
(Sigma-Aldrich), or both, and imaged for gap size
measurement. Three nonoverlapping representative
images from each of the gapped areas were acquired
to estimate the relative migration of cells. Each condi-
tion was examined in triplicate experiments.
2.9. Mass spectrometry (MS)-based proteomic
analysis
Cells were processed according to the in stage tip sam-
ple preparation method (Kulak et al., 2014). Briefly,
250 µL of the reducing and alkylating sodium deoxy-
cholate buffer (PreOmics) was added to the samples
before protein denaturation at 99 °C and 1500 g for
10 min. Samples were further solubilized using the
bioruptor for 10 min and digested by trypsin and Lys-
C (1 : 100) overnight at 37 °C and up to 2000 g. Fol-
lowing peptide desalting using SDB-RPS, samples were
measured on an quadrupole–Orbitrap mass spectrome-
ter (Scheltema et al., 2014; Kelstrup et al., 2014) (Q
Exactive HF; Thermo Fisher Scientific, Rockford, IL,
USA) coupled to an EASYnLC 1200 ultra-high-pres-
sure system (Thermo Fisher Scientific). About 0.5 µg
of peptides were loaded on a 45-cm HPLC column
(75 lm inner diameter; in-house-packed using Repro-
Sil-Pur C18-AQ 1.9 µm silica beads; Dr. Maisch
GmbH, Ammerbuch, Germany). Peptides were sepa-
rated using a linear 100 min gradient from 3% to 23%
B in 82 min and stepped up to 40% in 8 min at
350 nL per min where solvent A was 0.1% formic acid
in water and solvent B was 80% acetonitrile and 0.1%
formic acid in water. Column temperature was kept at
60 °C. The mass spectrometer was operated in ‘top-15’
data-dependent mode, collecting MS spectra in the
Orbitrap mass analyzer (60 000 resolution, 300–
1650 m/z range) with a maximum ion injection time of
25 ms and an automatic gain control (AGC) target of
3E6. The most intense ions from the full scan were iso-
lated with a width of 1.4 m/z. Following higher-energy
collisional dissociation with a normalized collision
energy of 27%, MS/MS spectra were collected in the
Orbitrap (15 000 resolution) with a maximum ion
injection time of 28 ms and an AGC target of 1E5.
Precursor dynamic exclusion was enabled with a dura-
tion of 30 s. Spectra were searched against the 2015
UniProt human databases (UP000005640_9606 and
UP000005640_9606_additional) using MaxQuant ver-
sion 1.5.3.34 with a 1% FDR at the peptide and pro-
tein level and default settings. The ‘match between
runs’ feature was on with a matching time window of
0.7 min and an alignment time window of 20 min.
Label-free quantification was performed using the
MaxLFQ algorithm with a minimum ratio count of 1.
Following bioinformatic analyses were performed
using the PERSEUS software (Tyanova et al., 2016) (ver-
sion 1.5.5.0). Proteins that were identified in the decoy
reverse database or only by site modification were
removed for data analysis. The MS proteomics data
have been deposited to the ProteomeXchange Consor-
tium via the PRIDE (Vizcaino et al., 2016) partner
repository and are available upon request.
3. Results
3.1. Transcriptome profiling of DLD-1 wt and
DLD-1 G13D cells
To address the molecular mechanisms underlying the
differential invasive phenotype we had observed in
KRAS-mutated cells exposed to TIMP-1 (Tarpgaard
et al., 2016), we performed genome-wide mRNA
expression profiling of the DLD-1 wt and DLD-1
G13D cell lines (dataset provided as Data S1). Given
that the two cell lines are isogenic, only differing in
their KRAS mutational status, we first determined
whether we could find any biologically relevant linear
dimensions in the expression dataset that would differ-
entiate between the two cell lines. Principal component
analysis (PCA) of our dataset showed that the two cell
lines could be separated on the basis of their three
main principal components (PC-#1, PC-#2, and PC-
#3, respectively; Fig. 1A). We then compared the two
cell lines’ mRNA profiles and found only rather mod-
erate differences in mRNA expression between the two
lines. The 25 most highly up- or down-regulated tran-
scripts are presented in Table 1. Two differentially
expressed genes (Table 1) called our attention: the KIT
proto-oncogene RTK (c-Kit), a key regulator of cell
survival, proliferation, and migration (Lennartsson
and R€onnstrand, 2012), and tripartite motif-containing
59 (TRIM59) protein, which is known to affect CRC
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proliferation and metastasis (Sun et al., 2017). These
two genes stood out, not only because they are known
to affect CRC cell invasion, but also, importantly,
because they were present in a set of 58 hits we discov-
ered in a yeast two-hybrid (Y2H) screening for TIMP-
1 potential interaction partners (M. Hoeberg, personal
communication).
3.2. Proteome profiling of DLD-1 wt and DLD-1
G13D cells
To further address the molecular mechanisms underly-
ing the TIMP-1-dependent differential invasive pheno-
type we observed in KRAS-mutated cells, we
performed MS-based proteomic analysis of the DLD-1
wt and DLD-1 G13D cell lines. We quantified a total
of 5861 proteins (Data S2). Again, PCA along the two
main principal components segregated the two cell
lines, with the main component driving the separation
being proteins within the GO class ‘mitotic cell cycle’.
This observation is consistent with the presence of the
oncogenic KRAS G13D allele in DLD-1 G13D cells,
and a higher proliferative potential than DLD-1 wt
cells. Among the proteins identified as being differen-
tially expressed between the two cell lines, we identified
c-Kit (Fig. 1B), which was concordant with our
mRNA expression data (Table 1). TRIM59 was not
present in our protein dataset, so we could not confirm
its deregulation. We confirmed the decreased c-Kit
expression in DLD-1 G13D cells compared to wt cells
by western blot analysis of cellular extracts (CE;
Fig. 1C) and immunofluorescence (Fig. 1D). As the
extracellular domain of c-Kit can be shed to the extra-
cellular environment following proteolytic cleavage, it
was conceivable that the difference in cellular expres-
sion we had observed was due to substantially
increased protein shedding to the extracellular space,
rather than true differential expression (Yee et al.,
1994; Yee et al., 1993). Analysis of conditioned media
(CM) showed this not to be the case (CM; Fig. 1C), as
Fig. 1. (A) PCA plot of expression microarray data of DLD-1 wt (red circles) and DLD-1 G13D (blue circles) cell lines. The percentages of the
total variation that are accounted for by the 1st, 2nd, and 3rd principal components are shown on the x-, y-, and z-axes labels, respectively.
(B) PCA plot of comparative analysis between DLD-1 wt and DLD-1 G13 protein expression data, respectively. Proteins within the GO class
‘mitotic cell cycle’ are highlighted (magenta). c-Kit is also pinpointed (red). (C) Upper panel: immunoblot analysis of c-Kit and p150Glued
(normalizing control) protein expression in DLD-1 wt and DLD-1 G13D cells grown in media with serum (+FBS) and sereum free media
(SFM), respectively, lower panel: graph depicting pooled densitometry measurements of c-Kit levels relative to those of p150Gluedin DLD-1
wt and DLD-1 G13D CE and CM, respectively. Data points are presented as mean  SEM of triplicate experiments. (D) c-Kit expression
was examined in both DLD-1 wt and DLD-1 G13D cells by immunocytochemistry. Sections were immunofluorescently stained for c-Kit (red)
and the cell nucleus (DAPI, blue), respectively. Scale bar = 20 µm.
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the amount of extracellular c-Kit present in CM of
DLD-1 G13D cells was markedly lower than the levels
observed in CM of DLD-1 wt cells. In both cases, the
extracellular expression of c-Kit was proportional to
the cellular levels of c-Kit (Fig. 1C; compare c-Kit in
DLD-1 wt CE to CM and DLD-1 G13D CE to CM,
respectively).
3.3. TIMP-1 interacts with the cellular membrane
in DLD-1 wt and DLD-1 G13D cells
Previous studies indicated that the cellular effects of
TIMP-1 may be mediated by direct binding to a cell
surface receptor, an assumption emphasized by the
identification of the tetraspanin CD63 as a TIMP-1
cell surface interacting protein in a complex with b1
integrin (Jung et al., 2006; Toricelli et al., 2013; Wilk
et al., 2013). Furthermore, uptake of TIMP-1 in breast
cancer cells has also been reported in co-culture sys-
tems, suggesting that cancer cells can bind and inter-
nalize exogenous TIMP-1 (Kuvaja et al., 2012; Ritter
et al., 1999). We investigated whether DLD-1 wt cells
or DLD-1 G13D cells can bind and internalize exoge-
nously added human recombinant TIMP-1 (Vinther
et al., 2014), and whether the profile of cellular inter-
nalization of TIMP-1 differed between the two cell
lines. TIMP-1 was added to the culture media of
DLD-1 wt and DLD-1 G13D cells, and samples were
collected at different time points and analyzed (Fig. 2).
We found that both DLD-1 wt cells and DLD-1
G13D cells could bind TIMP-1, although the interac-
tion differed between the two cell lines. In both cases,
TIMP-1 binding showed a bimodal behavior (Fig. 2A,
B): a fast (1 min) but transient interaction in a first
Table 1. List of top 25 genes, which showed differential expression between DLD-1 wt and DLD-1 G13D, ranked by P-value, with cut off
Log2 FoldChange>+/-1.
Gene Log2FoldChange P-value
Symbol Name
wt vs
G13D
wt vs
wt + TIMP-
1
G13D vs
G13D + TIMP-
1
wt vs
G13D
wt vs
wt + TIMP-
1
G13D vs
G13D + TIMP-
1
1 S100P S100 calcium binding protein P 3.30 0.10 0.40 0.00000 0.691 0.138
2 PDZK1IP1 PDZK1 interacting protein 1 1.72 0.10 0.30 0.00001 0.657 0.209
3 SH3BGRL SH3 domain binding glutamate-rich
protein-like
1.50 0.33 0.09 0.00003 0.168 0.699
4 KBTBD11 Kelch repeat and BTB (POZ) domain-
containing 11
1.68 0.09 0.39 0.00004 0.742 0.172
5 HAGH Hydroxyacylglutathione hydrolase 1.74 1.56 0.39 0.00006 0.000 0.198
6 KLK7 Kallikrein-related peptidase 7 1.74 0.17 0.50 0.00006 0.558 0.104
7 NPPB Natriuretic peptide B 1.90 0.12 0.49 0.00006 0.715 0.138
8 CYB5A Cytochrome b5 type A (microsomal) 1.55 0.20 0.51 0.00008 0.465 0.075
9 TRIM59 Tripartite motif-containing 59 1.46 0.26 0.43 0.00009 0.326 0.114
10 PPT2 palmitoyl-protein thioesterase 2 1.82 0.47 0.13 0.00018 0.188 0.714
11 KIT v-Kit Hardy–Zuckerman 4 feline
sarcoma viral oncogene homolog
1.33 0.33 0.08 0.00025 0.221 0.771
12 KRT20 keratin 20, type I 1.99 0.35 1.07 0.00026 0.376 0.017
13 GFRA4 GDNF family receptor alpha 4 1.96 1.68 0.20 0.00028 0.001 0.605
14 SEZ6L2 Seizure-related 6 homolog (mouse)-
like 2
1.25 0.26 0.11 0.00029 0.320 0.651
15 ICAM2 intercellular adhesion molecule 2 1.76 0.07 0.73 0.00035 0.852 0.063
16 LKAAEAR1 LKAAEAR motif-containing 1 1.89 1.50 0.38 0.00042 0.002 0.350
17 KIAA1211L KIAA1211-like 1.28 1.02 0.17 0.00046 0.002 0.541
18 B3GNT9 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 9
1.23 0.11 0.39 0.00055 0.693 0.158
19 DENND2D DENN/MADD domain-containing 2D 1.21 0.01 0.07 0.00057 0.957 0.800
20 PDE4D Phosphodiesterase 4D, cAMP-specific 2.60 0.29 1.59 0.00057 0.615 0.015
21 FOXB1 Forkhead box B1 1.58 1.37 0.81 0.00059 0.002 0.035
22 LOXL1 Lysyl oxidase-like 1 1.11 0.19 0.43 0.00066 0.447 0.100
23 LAGE3 L antigen family, member 3 1.75 0.49 1.06 0.00075 0.226 0.018
24 NMB Neuromedin B 1.15 0.12 0.39 0.00086 0.654 0.159
25 TNNT1 Troponin T type 1 (skeletal, slow) 1.24 0.14 0.58 0.00086 0.638 0.062
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step, followed by a slower second step where we
observed continuously increasing interaction of TIMP-
1 until a stable state was reached sometime between 2
and 4 h, indicating the binding/internalization process
had reached equilibrium (Fig. 2B). The only detectable
difference between the two cell lines concerned the first
interaction, where levels of bound TIMP-1 protein
were significantly higher in DLD-1 G13D than in
DLD-1 wt (Fig. 2A).
Given that this assay does not discriminate between
TIMP-1 bound to a receptor on the cell surface and
protein that has been internalized, we performed
immunolocalization of TIMP-1. We found that exoge-
nously added TIMP-1 localized mainly to the mem-
brane (Fig. 2C). Trypsinization of cells prior to
analysis of interacting TIMP-1 revealed that most of
the exogenous TIMP-1 protein that interacted with
DLD-1 G13D or DLD-1 wt cells, respectively, could
be removed by trypsinization of cells prior to analysis.
These observations suggest that in the case of DLD-1
G13D and DLD-1 wt cells, exogenous TIMP-1 could
bind to the cell surface but was not internalized, at
least at any detectable rate (Fig. 2D).
3.4. TIMP-1 has different effects on DLD-1 wt
and DLD-1 G13D cells
Having established a gene expression baseline for
DLD-1 wt and DLD-1 G13D cells, we examined what
changes took place upon cell exposure to exogenous
TIMP-1. DLD-1 wt and DLD-1 G13D cells were cul-
tured in the presence, or absence, of TIMP-1
(5 µgmL1) for 4 h, and their transcriptomes were
profiled as before. For the analysis of the gene expres-
sion dataset, Log2FoldChange and statistical signifi-
cance were calculated (P < 0.05, t-test with correction
for multiple hypothesis testing) (Benjamini and Hoch-
berg, 1995). However, this analysis gave no significant
hits, and we repeated the analysis with a lower strin-
gency (P < 0.0075, t-test with no multiple hypothesis
correction). We found that only seven genes were sig-
nificantly changed by TIMP-1 exposure in DLD-1 wt
cells (Table 2), whereas 1183 genes were affected in
DLD-1 G13D cells (Table 3). Clearly, the extent of the
overall effect of TIMP-1 was much greater in the
KRAS-mutated cells than in the KRAS wt cells, and it
was conceivable that the cumulative effect of the
changes brought about by exposure to TIMP-1 could
account for the differential effect of TIMP-1 on the
KRAS-mutated cells. Noteworthy, neither c-Kit nor
TRIM59 expression were affected by TIMP-1
(Table 1). Interestingly, we found that five genes,
which were significantly up-regulated upon TIMP-1
stimulation in DLD-1 G13D cells but showed no
change in DLD-1 wt cells, mapped to the Ras-Raf-
MEK-Erk/JNK signaling axis (Table 4), indicating
that TIMP-1 may sustain increased activity in the Ras
signaling axis in cells expressing oncogenic Ras, which
may result in reinforced signaling through this path-
way.
3.5. Kinome profiling of DLD-1 wt and DLD-1
G13D cells exposed to TIMP-1
TIMP-1 has been shown to effect several distinct sig-
naling pathways, including the mitogen-activated pro-
tein kinase (MAPK) pathway and cAMP–protein
kinase A pathway, and to be associated with activation
of RAS and ERK, as well as PI3-K induced Cyclin D
expression. TIMP-1 has also been reported to increase
AKT activity (Akahane et al., 2004; Lu et al., 2011;
Stetler-Stevenson, 2008). Given that multiple associa-
tions with signaling pathways have been reported for
TIMP-1 and that these appear to be contextual, we
performed a screening for kinases that may specifically
be involved in TIMP-1-mediated CRC cellular signal-
ing (Chirco et al., 2006; Stetler-Stevenson, 2008). Tak-
ing the patterns of association of exogenous TIMP-1
with DLD-1 G13D and wt cells in consideration
(Fig. 2), we analyzed the kinome of DLD-1 wt and
DLD-1 G13D cells, respectively, immediately before
addition of exogenous TIMP-1 to the growth medium,
and after 15, 30, and 120 min of adding TIMP-1
(Fig. 3D). Significant hits are reported in Fig. 3.
TIMP-1 stimulation had quite distinct effects on the
two different cell lines (Fig. 3). For both TKs
(Fig. 3A) and STKs (Fig. 3B), a general increase in
kinase activity appeared in DLD-1 wt cells exposed to
exogenous TIMP-1 for 30 min. For TKs only, a subse-
quent decrease was detected after 120 min compared
to control cells (Fig. 3A). This pattern was different
for DLD-1 G13D, where significant inhibition of TK
and STK activity, rather than activation, was observed
upon 15 min of TIMP-1 exposure followed by minor,
nonsignificant, increases in TK activity after 30 and
120 min. This suggests KRAS-dependent differences in
TIMP-1 signaling dynamics. Table 5 shows the top 10
hits for the ranking of active kinases derived from the
STK and TK array analysis for A) protein TKs and
B) STKs. Ranking is based on the sum of sensitivity
(significance of the difference between samples) and
specificity (specificity of the mapping to specific
upstream kinases). One hit was particularly suggestive:
c-Kit, which we had found in our transcriptome and
proteome profiling of DLD-1 wt and DLD-1 G13D
cells to be up-regulated in DLD-1 wt cells compared
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Fig. 2. Presence and localization of exogenously added TIMP-1 to DLD-1 wt and G13D cells. (A, B) DLD-1 wt and G13D cells were grown in
the presence (or not) of TIMP-1 (5 µgmL1) for the indicated amount of time. Cells were washed extensively, and whole-cell extracts were
examined by western blotting. Upper panels: immunoblots showing levels of TIMP-1 protein present in whole-cell extracts. b-Actin was
used as normalizing control. Lower panels: graphs depicting pooled densitometry measurements of TIMP-1 levels relative to those of b-
actin. Data points are presented as mean  SEM of triplicate experiments. (C) Immunostaining of DLD-1 wt and G13D cells grown in the
presence of TIMP-1. Cells were grown in chamber slides and exposed to 5 µgmL1 TIMP-1 for the indicated amount of time. Controls
were grown in the absence of TIMP-1. Cells were fixed and immunofluorescently stained for TIMP-1 (red) and the cell nucleus (DAPI, blue),
respectively. Scale bars, 20 µm. (D) DLD-1 wt and G13D cells were grown in the presence of TIMP-1 (5 µgmL1) for the indicated amount
of time. Cells were washed extensively and trypsinized prior lysis and analysis of TIMP-1 presence in whole-cell extracts by western
blotting. P150Glued was used as normalizing control.
Table 2. Significantly deregulated genes in DLD-1 wt cells exposed to TIMP-1.
Symbol Name Log2FoldChange P-value
1 HAGH hydroxyacylglutathione hydrolase 1.56 0.00016
2 GFRA4 GDNF family receptor alpha 4 1.68 0.00091
3 FOXB1 forkhead box B1 1.37 0.00176
4 LKAAEAR1 LKAAEAR motif-containing 1 1.50 0.00235
5 KIAA1211L KIAA1211-like 1.02 0.00246
6 ARTN Artemin 2.21 0.00599
7 PTH2 parathyroid hormone 2 1.03 0.00735
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to DLD-1 G13D cells, both at the mRNA (Table 1)
and at the protein levels (Fig. 1B), was on the list of
kinases (Table 3). MetaCore pathway mapping of
kinase hits, based on the enrichment distribution of
the kinase dataset, identified the c-Kit canonical sig-
naling pathway as the highest significant [log(P-
value) = 11] (Fig. 3C).
3.6. TIMP-1 increases c-Kit activity
Given that the Ras/MAPK and PI3K/Akt signaling
modules are effectors of the c-Kit signaling axis, and
immunoprecipitation studies have shown that c-Kit is
associated with the tetraspanin CD63, a TIMP-1
interactor, at the cellular membrane (Anzai et al.,
2002; Termini and Gillette, 2017), we investigated fur-
ther a possible connection between c-Kit and TIMP-1.
We performed co-immunoprecipitation studies with c-
Kit and TIMP-1, but were unable to detect any inter-
action, neither with a TIMP-1-specific antibody nor
with a tagged version of TIMP-1 (Fig. S1A,B, respec-
tively), under the conditions assayed. PLA, a method
that allows one to visualize protein–protein interac-
tions in situ, allowed us to confirm that c-Kit was in
physical proximity of TIMP-1, as we detected a num-
ber of fluorescent signals in DLD-1 wt cells (Fig. S1C,
panel a, white arrows), suggestive of an interaction
between c-Kit and TIMP-1, whereas very few signals
Table 3. List of top 25 genes, ranked by P-value, affected by TIMP-1 in DLD-1 G13D cells.
Symbol Description Log2FoldChange P-value
1 EVX1 Even-skipped homeobox 1 1.32 0.0018
2 STX10 Syntaxin 10 1.81 0.0020
3 ZNF692 Zinc finger protein 692 2.17 0.0020
4 MC1R Melanocortin 1 receptor (alpha melanocyte-stimulating hormone receptor) 1.91 0.0021
5 RASL10A RAS-like, family 10, member A 1.72 0.0021
6 LZTS2 Leucine zipper, putative tumor suppressor 2 1.60 0.0023
7 EREG Epiregulin 1.84 0.0024
8 FAM173A Family with sequence similarity 173, member A 1.85 0.0025
9 PPIE Peptidylprolyl isomerase E (cyclophilin E) 1.55 0.0026
10 CRYBA2 Crystallin, beta A2 2.11 0.0026
11 TCIRG1 T-cell, immune regulator 1, ATPase, H + transporting, lysosomal V0 subunit A3 1.76 0.0028
12 GGA1 Golgi-associated, gamma adaptin ear-containing, ARF binding protein 1 2.07 0.0028
13 EDF1 Endothelial differentiation-related factor 1 1.61 0.0028
14 GYLTL1B Glycosyltransferase-like 1B 1.87 0.0028
15 SQLE Squalene epoxidase 3.22 0.0028
16 TELO2 Telomere maintenance 2 2.09 0.0028
17 C14orf80 Chromosome 14 open reading frame 80 2.25 0.0029
18 WDR6 WD repeat domain 6 1.76 0.0029
19 CD151 CD151 molecule (Raph blood group) 2.05 0.0029
20 ASIC1 acid sensing (proton gated) ion channel 1 1.37 0.0029
21 DBET D4Z4 binding element transcript (nonprotein coding) 1.93 0.0029
22 USP20 Ubiquitin specific peptidase 20 1.44 0.0029
23 RECQL4 RecQ protein-like 4 1.63 0.0029
24 HMG20B High mobility group 20B 1.84 0.0030
25 CKS2 CDC28 protein kinase regulatory subunit 2 -2.61 0.0030
Table 4. Selected hits from the Ras-Raf-MEK-Erk/JNK signaling axis significantly up-regulated upon TIMP-1 stimulation in DLD-1 G13D cells.
Log2FoldChange P-value
Gene wt vs G13D wt vs wt + TIMP-1 G13D vs G13D + TIMP-1 wt vs G13D wt vs wt + TIMP-1 G13D vs G13D + TIMP-1
RAF1 0.05 0.01 1.93 0.9291 0.9834 0.0068
MAP3K1 0.58 0.05 2.20 0.3576 0.9340 0.0036
MAP3K3 0.21 0.09 1.64 0.6709 0.8587 0.0056
MAP3K6 0.40 0.03 2.10 0.5012 0.9612 0.0035
MAP4K2 0.18 0.22 1.63 0.7054 0.6521 0.0047
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were detected in DLD-1 G13D cells, which express c-
Kit at much lower levels (Fig. S1C, panel b, white
arrows, and Fig. 1B).
Given that c-Kit was among the top hits in our
kinase analysis, we decided to investigate c-Kit activity
upon TIMP-1 stimulation. c-Kit phosphorylation was
used as a measure of c-Kit activity. Phosphorylation
of all tested c-Kit phosphorylation sites increased
significantly upon exposure of DLD-1 wt or DLD-1
G13D cells to TIMP-1 stimulation (Fig. 4A–D, respec-
tively). To investigate whether TIMP-1-increased phos-
phorylation of c-Kit is followed by phosphorylation
downstream targets of c-Kit, p-ERK levels were also
examined. We found increased (twofold) p-ERK levels
upon 5 min of TIMP-1 stimulation in DLD-1 wt
(Fig. 4B).
Fig. 3. Kinase activity regulation results from PamGene analysis. DLD-1 wt and DLD-1 G13D cells were exposed (or not) with 5 lgmL1
TIMP-1 for 15, 30, and 120 min and analyzed with PamGene kinase activity assay. The tables show significantly (P < 0.05) TIMP-1-regulated
kinase activities of (A) protein TKs and (B) STKs (Red and blue are significant, P < 0.05; red denotes up-regulation, and blue down-
regulation, respectively). Statistical tests were performed with PamGene’s Bionavigator software. (C) MetaCore pathway map visualization
of PamGene kinase array data for the c-Kit pathway. Kinases identified in our analysis are indicated by a histogram next to a network object
with activity denoted by bar height (D) Analysis of kinase activity of kinases linked to the c-Kit signaling axis upon exposure to TIMP-1.
Kinase activity raw data were extracted for c-Kit-related kinases (PI3K, PLCc, RAF1, PDK1, and paxilin). The figure shows the mean fold
change between the results of the control and TIMP-1-stimulated samples. Kinase activity was significantly down-regulated upon 120 min in
DLD-1 wt, except for RAF1, which was borderline significant (P < 0.10).
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Another level of regulation of c-Kit function
includes proteolytic extracellular cleavage allowing
release of a surface protein ectodomain (‘shedding’)
that produces a soluble form of c-Kit. This reduces cell
surface expression as well as produces a soluble c-Kit
polypeptide, which can competitively bind the c-Kit
ligand SCF. Stimulating DLD-1 wt with either 5 or
50 lgmL1 TIMP-1 significantly decreased soluble
Table 5. Kinase analysis of TIMP-1-mediated effects.
Tyrosine kinases Serine/threonine kinases
1 Insulin receptor (INSR) 1 Spleen tyrosine kinase (SYK)
2 Insulin-like growth factor 1 receptor (IGF1R) 2 B lymphocyte kinase (BLK)
3 Insulin receptor-related protein (INSRR) 3 Hepatocyte growth factor receptor (MET)
4 NT-3 growth factor receptor (NTRK2) 4 Fibroblast growth factor receptor 3 (FGFR3)
5 High-affinity nerve growth factor receptor (NTRK1) 5 Abelson murine leukemia viral oncogene homolog 1 (ABL)
6 v-Kit Hardy–Zuckerman 4 feline sarcoma viral oncogene
homolog (c-Kit)
6 Receptor tyrosine-protein kinase erbB-3 (ERBB3)
7 Fibroblast growth factor receptor 4 (FGFR4) 7 Serine/arginine repetitive matrix protein 1 (SRMS)
8 Proto-oncogene tyrosine-protein kinase Src (SRC) 8 Gardner–Rasheed feline sarcoma viral (v-fgr) oncogene homolog (FGR)
9 Tyrosine-protein kinase Lyn (LYN) 9 Macrophage-stimulating protein receptor (MST1R/RON)
10 Lymphocyte-specific protein tyrosine kinase (LCK) 10 Related to receptor tyrosine kinase (RYK)
Fig. 4. Phosphorylation of c-Kit upon TIMP-1 exposure. (A and C) DLD-1 wt and G13D cells were stimulated with either 1 or 5 µgmL1
TIMP-1 for the indicated time periods. Controls were treated with vehicle (PBS) for 30 min. Western blots were repeatedly stripped and
probed for the different anti-phospho-c-Kit antibodies recognizing various phosphorylated residues (Y703, Y721, Y568, Y823, and Y936 for
DLD-1 wt and Y568 and Y936 for DLD-1 G13D, respectively) and finally for total c-Kit. Blots were additionally blotted for pERK1/2 and TIMP-
1. b-Actin was used as loading control. (B) Quantification of phosphorylated c-Kit and total c-Kit levels upon TIMP-1 exposure in DLD-1 wt
cells. Quantification was performed with ImageJ. The mean fold change of c-Kit pY703, c-Kit pY721, and total c-Kit levels between
unstimulated and TIMP-1-treated samples is presented (SEM). * indicates P < 0.05, and ** indicates P < 0.01, a two-way ANOVA test
with Dunnett’s correction for multiple comparison was used for significance. (D) Analysis of c-Kit shedding upon exposure to TIMP-1. Cells
were stimulated for 24 h with 5 or 50 µgmL1 TIMP-1 prior to collection of conditioned medium. Soluble c-Kit levels in the medium were
determined by a c-Kit shedding-specific ELISA kit. Bars represent the mean fold change of soluble c-Kit levels between control and TIMP-1-
stimulated samples (SEM). No shed c-Kit was detected for DLD-1 G13D. *** and **** indicate P < 0.001 and P < 0.0001, respectively.
Significance was determined by one-way ANOVA test with Dunnett’s correction for multiple comparison.
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c-Kit levels in the media down to ~ 60% and ~ 50%,
respectively (Fig. 4D, black vs gray bars). These data
are consistent with a previous observed decreased
levels of soluble c-Kit upon incubation of mast cells
with TIMP-1 and TIMP-3 (Cruz et al., 2004). To
determine whether the effect of TIMP-1 on c-Kit acti-
vation we observed was a DLD-1 wt cell-specific
effect, we examined levels of pY703 c-Kit in Ba/F3
cells upon exposure to TIMP-1. Ba/F3 is a murine,
interleukin (IL)-3 dependent, hematopoietic cell line
(Palacios and Steinmetz, 1985). We found that TIMP-
1 induced activation of c-Kit, measured by increased
phosphorylation of pY703 (Fig. 5A).
4. Discussion
Several studies have reported that plasma levels of
TIMP-1 have prognostic value in CRC (Birgisson
et al., 2010; Nielsen et al., 2010). Although TIMP-1
expression is up-regulated in colorectal tumor tissue
(Lu et al., 1991), the molecular mechanisms underlying
the prognostic effect of TIMP-1 in CRC remain
unclear. We previously reported a differential cellular
effect of TIMP-1 on CRC cell invasion, dependent on
KRAS status (Tarpgaard et al., 2016). A similar obser-
vation has also been reported for pancreatic ductal
adenocarcinoma, where exogenous addition of human
recombinant TIMP-1 significantly increased prolifera-
tion of pancreatic ductal cells, but only in KRAS-
transformed cells (Botta et al., 2013). To gain some
insight into the molecular mechanisms underlying the
KRAS-dependent effects of TIMP-1 in CRC, we exam-
ined a matched pair of isogenic human CRC DLD-1
cell line clones (KRAS G13D and wild-type) exposed,
or not, to TIMP-1. We performed genome-wide
mRNA expression profiling of the DLD-1 wt and
DLD-1 G13D cell lines (Table 1 and Fig. 1) and, from
the limited number of differentially expressed genes
between the two cell lines, identified two, c-Kit and
TRIM59, that could conceivably play a role in the
effects of TIMP-1 on CRC cells. These two genes
stood out, not only because they are known to affect
CRC cell invasion, but also, importantly, because they
were present in a set of 58 hits we discovered in a
Y2H screening for TIMP-1 potential interaction part-
ners (M. Hoeberg, personal communication). We com-
plemented the gene expression analysis of the DLD-1
wt and DLD-1 G13D cell lines with MS-based pro-
teome profiling and phosphopeptide array-based
kinome profiling. We found that all levels of our anal-
yses linked c-Kit, expression, and pathway activation,
with exposure of cells to TIMP-1. In fact, targeted
analysis of c-Kit activation showed that TIMP-1 sig-
nificantly increased the phosphorylation of c-Kit dock-
ing sites for GRB2 and P85 (pY703 and pY719) in
DLD-1 wt. GRB2 has a major role in being the adap-
ter protein linking the scaffolding protein GAB2 to c-
Kit. Activation of c-Kit leads to phosphorylation of
GAB2 and the recruitment of SHP2, which leads to
RAS/ERK pathway activation, as well as p85, which
Fig. 5. TIMP-1 effects on (A) Ba/F3 pro-B murine cells and (B) DLD-1 wt cells. (A) Ba/F3 cells were stimulated with 5 µgmL1 TIMP-1 for
the indicated time periods. Samples were analyzed for phospho- (Y703) and total c-Kit levels by western blot analysis. b-Actin was used as
loading control. Quantification was performed with IMAGEJ. The mean fold change of c-Kit pY703, and total c-Kit levels between unstimulated
and TIMP-1-treated samples are presented (SEM); a two-way ANOVA test with Dunnett’s correction for multiple comparison was used for
significance. (B) Light micrographs of wounded cell monolayers showing effect of TIMP-1 on wound closure of DLD-1 wt cells at 24 h. Cells
were exposed to imatinib mesylate (10 µM), TIMP-1 (5 µgmL1), or a combination of both. Representative images are shown.
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in turn leads to PI3-K pathway activation (Sun et al.,
2008). In addition, the increased phosphorylation of c-
Kit observed in DLD-1 G13D suggests that TIMP-1
causes c-Kit phosphorylation independently of KRAS
mutational status, though the levels of phosphorylated
c-Kit still differed, presumably due to the difference in
total c-Kit levels. These results showed that TIMP-1
increased phosphorylation, and therefore c-Kit activ-
ity, as well as increased the activity of c-Kit canonical
targets (Fig. 4). Activation of c-Kit by TIMP-1 was
not a cell-line-specific event, as we observed the same
effect in Ba/F3 pro-B murine cells (Fig. 5A). These
observations raise two major questions, how does
TIMP-1 cause activation of c-Kit and is there a bio-
logical significance for this activation?
Addressing the first question, protein interaction
analysis, be it co-immunoprecipitation or pull-down
assays, failed to show any physical interaction between
TIMP-1 and c-Kit (Fig. S1A). We did detect a number
of interactions using an in situ assay (Fig. S1B), but the
number of interaction was very low compared to the
presence of c-Kit at the membrane (Fig. 1D) and the
availability of TIMP-1 (Fig. 2C). With the caveat of a
very transient interaction between TIMP-1 and c-Kit,
our data were suggestive of physical proximity rather
than a direct interaction between these two proteins.
TIMP-1 interacts with a CD63/b1-integrin receptor at
the cell membrane (Jung et al., 2006); c-Kit is also asso-
ciated with the tetraspanin CD63 (Anzai et al., 2002).
Tetraspanin-enriched microdomains (TEM) are func-
tional platforms, capable of regulating multiple cellular
processes, including ectodomain ‘shedding’ and signal-
ing (Termini and Gillette, 2017; Yanez-Mo et al., 2011).
We could, in fact, detect a significant effect of TIMP-1
on shedding of c-Kit (Fig. 4D), supporting the idea that
proximity of TIMP-1 and c-Kit mediated by association
within a TEM may be responsible for the activation of
c-Kit we observed.
Concerning the second question, on whether there is
a biological significance for the TIMP-1-mediated acti-
vation of c-Kit, we investigated the ability of TIMP-1
to stimulate migration and proliferation of DLD-1 wt
cells, using an in vitro wound healing assay (Fig. 5B).
We found that wound closure in DLD-1 wt cells stim-
ulated with TIMP-1 was complete (100% confluency
in the wound area) whereas in DLD-1 wt cells, where
no TIMP-1 was added or where c-Kit signaling was
inhibited wound closure was delayed (~ 75% conflu-
ency in the wound area). These data suggest a TIMP-
1-mediated effect on cell migration and proliferation in
c-Kit-expressing CRC cells. These data are congruent
with results from a recent study that showed that a
subpopulation of endogenous cardiac stem cells, which
express c-Kit and CD63 (CD63+ve/c-Kit+ve), was driven
to proliferate, express cardiogenic factors, and differ-
entiate into major cardiac cell types upon stimulation
with TIMP-1 (Abdelli and Singla, 2015).
5. Conclusions
In conclusion, we identified c-Kit as a potential media-
tor of TIMP-1 function in CRC cells and showed that
TIMP-1 can mediate activation of c-Kit and prevent
ectodomain shedding. Given the growing attention
that c-Kit has been gaining as an important oncogene
in CRC (Attoub et al., 2002; Zhang et al., 2014) and
the role it plays in regulation of cell proliferation and
migration, it is likely that some of the biological effects
of TIMP-1 overexpression in CRC may be exerted
through its effect on c-Kit signaling. However, the
KRAS-associated effect of TIMP-1 on CRC cell inva-
sion cannot be explained by its potentiation of c-Kit
signaling alone, as this took place independently of
RAS status. We did find KRAS status-associated dif-
ferences between the two cell lines both in terms of
association with TIMP-1 where levels of bound TIMP-
1 protein were significantly higher in DLD-1 G13D
than in DLD-1 wt (Fig. 2A), and in terms of expres-
sion of genes affected by TIMP-1 where we found that
only seven genes were significantly changed by TIMP-
1 exposure in DLD-1 wt cells (Table 2), whereas 1183
genes were affected in DLD-1 G13D cells (Table 3).
Five genes in particular, which were significantly up-
regulated upon TIMP-1 stimulation in DLD-1 G13D
cells but showed no change in DLD-1 wt cells, were
interesting as they all mapped to the Ras-Raf-MEK-
Erk/JNK signaling axis (Table 4). It is conceivable
that TIMP-1 may cause increased activity in the Ras
signaling axis in cells expressing oncogenic Ras, result-
ing in persistent enhanced signaling through this path-
way, which would explain the worse outcome we
observed in CRC patients in association with TIMP-1
expression (Tarpgaard et al., 2016), but further studies
will be needed to clarify these observations.
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Fig. S1. Interaction analysis of TIMP-1 and c-Kit. (A)
DLD-1 wt and DLD-1 G13D cells were transfected
with GFP or GFP-TIMP-1 24 h prior to lysis.
Immunoprecipitation of lysates was performed with
GFP-TRAPs. TIMP-1 and c-Kit were examined in
samples of untransfected cells (Ctrl), input (IN),
unbound (UB), and immunoprecipitated fraction (IP)
using western blot analysis. (B) DLD-1 wt and DLD-1
G13D cells were exposed to 5 µgmL1 TIMP-1 or
vehicle for 30 min prior to lysis. Co-IP of lysates was
performed with protein G sepharose and either mouse
anti-IgG control or VT4 (anti-TIMP-1 antibody).
TIMP-1 and c-Kit were examined in input, unbound
and immunoprecipitated (Bound) fraction using west-
ern blot analysis. P150Glued was examined to ensure
true immunoprecipitation. The immunoprecipitation of
TIMP-1 was successful, however, c-Kit was not
detected in the immunoprecipitated fraction. (C) PLA
of c-Kit and TIMP-1. DLD-1 wt (a) and DLD-1
G13D (b) cells were stimulated with 5 lgmL1 TIMP-
1 for 30 min prior to fixing and embedding. Embedded
cell sections were examined for TIMP-1 and c-Kit
proximity, detected as red dots by PLA assay, and cell
nucleus were stained (DAPI, blue). (Representative
pictures are shown, scale bars 20 lm).
Table S1. Antibodies used in this study.
Data S1. Gene expression data.
Data S2. Mass spectrometry proteomics data.
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